Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

Journal of the American Academy of Dermatology

Volumn 77, Issue 5, 2017, Pages 902-910.e2

  Dai, Julia ^a,b   Belum, Viswanath R ^a   Wu, Shenhong ^c,d   Sibaud, Vincent ^e   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo

Indexed keywords

ANTINEOPLASTIC AGENT; CABOZANTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; IPILIMUMAB; NIVOLUMAB; PAZOPANIB; PEMBROLIZUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DEPIGMENTATION; HAIR COLOR; HUMAN; HYPERPIGMENTATION; MALIGNANT NEOPLASM; META ANALYSIS; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALE; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PIGMENTATION DISORDERS; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PIGMENTATION DISORDERS; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 85029413478     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2017.06.044     Document Type: Article

References (114)

1. Soreide, K., Berg, M., Skudal, B.S., Nedreboe, B.S., Advances in the understanding and treatment of colorectal cancer. Discov Med 12 (2011), 393–404.
2. Ricciardi, S., Tomao, S., de Marinis, F., Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10 (2009), 28–35.
3. Vokes, E.E., Chu, E., Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20 (2006), 15–25.
4. Jost, M., Kari, C., Rodeck, U., The EGF receptor, an essential regulator of multiple epidermal functions. Eur J Dermatol 10 (2000), 505–510.
5. Balagula, Y., Lacouture, M.E., Cotliar, J.A., Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 8 (2010), 149–161.
6. Wagner, L.I., Berg, S.R., Gandhi, M., et al. The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer 21 (2013), 1033–1041.
7. Rosen, A.C., Case, E.C., Dusza, S.W., et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14 (2013), 327–333.
8. Boone, S.L., Rademaker, A., Liu, D., Pfeiffer, C., Mauro, D.J., Lacouture, M.E., Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72 (2007), 152–159.
9. Ensslin, C.J., Rosen, A.C., Wu, S., Lacouture, M.E., Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 69:5 (2013), 708–720.
10. Valentine, J., Belum, V.R., Duran, J., et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol 72 (2015), 656–667.
11. Nishida, T., Shirao, K., Sawaki, A., et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 13 (2008), 244–251.
12. Hersh, E.M., O'Day, S.J., Powderly, J., et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 29 (2011), 489–498.
13. Bible, K.C., Suman, V.J., Molina, J.R., et al. A multicenter phase II trial of pazopanib in metastatic and progress medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99:5 (2014), 1687–1693.
14. Bible, K.C., Suman, V.J., Menefee, M.E., et al. A multiinstitutional phase II trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97 (2012), 3179–3184.
15. Kloos, R.T., Ringel, M.D., Knopp, M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27 (2009), 1675–1684.
16. Curigliano, G., Pivot, X., Cortes, J., et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 22 (2013), 650–656.
17. Han, J.Y., Kim, H.Y., Lim, K.Y., et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer 79 (2013), 137–142.
18. Strosberg, J.R., Weber, J.M., Choi, J., et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 23:9 (2012), 2335–2341.
19. Kreisl, T.N., Smith, P., Sul, J., et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111 (2013), 41–48.
20. Chau, N.G., Hotte, S.J., Chen, E.X., et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23 (2012), 1562–1570.
21. Barrios, C.H., Hernandez-Barajas, D., Brown, M.P., et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118 (2012), 1252–1259.
22. Bang, Y.J., Kang, Y.K., Kang, W.K., et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 29 (2011), 1449–1458.
23. Uemura, H., Shinohara, N., Yuasa, T., et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into treatment, efficacy, and safety. Jpn J Clin Oncol 40:3 (2010), 194–202.
24. Escudier, B., Roigas, J., Gillessen, S., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27 (2009), 4068–4075.
25. Faivre, S., Raymond, E., Boucher, E., et al. Safety and efficacy of suntinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10 (2009), 794–800.
26. Kulke, M.H., Lenz, H.J., Meropol, N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26 (2008), 3403–3410.
27. Burstein, H.J., Elias, A.D., Rugo, H.S., et al. Phase II study of sunitinib malate, on oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008), 1810–1816.
28. Socinski, M.A., Novella, S., Brahmer, J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26 (2008), 650–656.
29. Saltz, L.B., Rosen, L.S., Marshall, J.L., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25 (2007), 4793–4799.
30. Hutterer, M., Nowosielski, M., Haybaeck, J., et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol 16:1 (2014), 92–102.
31. Fountzilas, G., Fragkoulidi, A., Kalogera-Fountzila, A., et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 65 (2010), 649–660.
32. Monk, B.J., Mas Lopez, L., Zarba, J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:22 (2010), 3562–3569.
33. Ahmed, M., Barbachano, Y., Riddell, A., Hickey, J., Newbold, K.L., Viros, A., Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165:2 (2011), 315–322.
34. George, S., Merriam, P., Maki, R.G., et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27:19 (2009), 3154–3160.
35. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
36. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
37. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
38. Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
39. Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 711–731.
40. Ribas, A., Puzanov, I., Dummer, R., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
41. Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007), 115–124.
42. Elisei, R., Schlumberger, M.J., Müller, S.P., et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:29 (2013), 3639–3646.
43. Sternberg, C.N., Davis, I.D., Deen, K.C., Sigal, E., Hawkins, R.E., An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology 87:6 (2014), 342–350.
44. van der Graaf, W.T., Blay, J.Y., Chawla, S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:9829 (2012), 1879–1886.
45. Escudier, B., Porta, C., Bono, P., et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32:14 (2014), 1412–1418.
46. Raymond, E., Dahan, L., Raoul, J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:6 (2011), 501–513.
47. Robert, C., Sibaud, V., Mateus, C., Cherpelis, B.S., Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol 39 (2012), 227–240.
48. Tsao, A.S., Kantarjian, H., Cortes, J., O'Brien, S., Talpaz, M., Imatinib mesylate causes hypopigmentation in the skin. Cancer 98 (2003), 2483–2487.
49. Cario-Andre, M., Ardilouze, L., Pain, C., Gauthier, Y., Mahon, F.X., Taieb, A., Imatinib mesilate inihibits melanogenesis in vitro. Br J Dermatol 155 (2006), 493–494.
50. Buchdunger, E., Cioffi, C.L., Law, N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:1 (2000), 139–145.
51. Heidary, N., Naik, H., Burgin, S., Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 58 (2008), 545–570.
52. Basso, F.G., Boer, C.C., Correa, M.E., et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer 17 (2009), 465–468.
53. McPherson, T., Sherman, V., Turner, R., Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 23 (2009), 82–83.
54. Picardo, M., Cardinali, G., The genetic determination of skin pigmentation: KITLG and the KITLG/c-Kit pathway as key players in the onset of human familial pigmentary diseases. J Invest Dermatol 131 (2011), 1182–1185.
55. Spritz, R.A., The molecular basis of human piebaldism. Pigment Cell Res, 5, 1992, 3403.
56. Grimes, P.E., New insights and new therapies in vitiligo. JAMA 293 (2005), 730–735.
57. Tarhini, A., Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo), 2013, 2013, 857519.
58. Weber, J.S., Kähler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
59. Pavlick, A.C., Ott, P.A., Kannan, K., et al. Hair depigmentation as an indicator of a durable response to CTLA-4 therapy. [abstract] J Clin Oncol, 28(suppl 15), 2010, 8571.
60. Hua, C., Boussemart, L., Mateus, C., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:1 (2016), 45–51.
61. Larsabal, M., Marti, A., Jacquemin, C., et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 76 (2017), 863–870.
62. Chang, G.C., Yang, T.Y., Chen, K.C., Yin, M.C., Wang, R.C., Lin, Y.C., Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004), 4646–4647.
63. Alexandrescu, D.T., Dasanu, C.A., Farzanmehr, H., Kauffman, C.L., Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J, 14(7), 2008, 7.
64. Prasad, N., Deshmukh, C., Biswas, G., Bakshi, A., Sastry, P.S., Parikh, P.M., Dermatological toxicity of imatinib mesylate. J Assoc Physicians India, 53, 2005, 298.
65. Hamza, I., Gaies, E., Kastalli, E., Daghfous, R., El Aidli, S., Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor. Therapie 69 (2014), 245–247.
66. Singh, N., Bakshi, S., Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol, 29, 2007, 208.
67. Ghunawat, S., Sarkar, R., Garg, V.K., Imatinib induced melasma-like pigmentation: report of five cases and review of literature. Indian J Dermatol Venereol Leprol 82 (2016), 409–412.
68. Valizadeh, N., Imatinib induced facial skin hyperpigmentation in a case of chronic myelogenous leukemia. Shiraz E-Medical J, 12(3), 2011.
69. Han, H., Yu, Y.Y., Wang, Y.H., Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. J Am Acad Dermatol 59 (2008), S80–S83.
70. Harris, J.E., Rashighi, M., Nguyen, N., et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74 (2016), 370–371.
71. Jalalat, S.Z., Cohen, P.R., Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation. Dermatol Online J, 19(10), 2013, 4.
72. Tsao, A.S., Kantarjian, H., Cortes, J., O'Brien, S., Talpaz, M., Imatinib mesylate causes hypopigmentation in the skin. Cancer 98 (2003), 2483–2487.
73. Raanani, P., Goldman, J.M., Ben-Bassat, I., Depigmentation in a chronic myeloid leukemia patient treated with STI-471. J Clin Oncol 20 (2002), 869–870.
74. Hasan, S., DInh, K., Lombardo, F., Dawkins, F., Kark, J., Hypopigmentation in an African patient treated with imatinib mesylate: a case report. J Natl Med Assoc 95 (2003), 722–724.
75. Grossman, W.J., Wilson, D.B., Hypopigmentation from imatinib mesylate (Gleevac). J Pediatr Hematol Oncol, 26, 2004, 214.
76. Brazzelli, V., Roveda, E., Prestinarl, F., et al. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colormetric assessment. Pediatr Dermatol 23 (2006), 175–178.
77. Legros, L., Cassuto, J.P., Ortonne, J.P., Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?. Br J Dermatol 153 (2005), 691–692.
78. McPartlin, S., Leach, M., Loss of skin pigment caused by imatinib therapy. Br J Haematol, 129, 2005, 448.
79. Cerchione, C., Fabbricini, R., Pane, F., Luciano, L., Vitiligo-like lesions in an adult patient treated with imatinib mesylate. Leuk Res 33:8 (2009), e104–e105.
80. Brazzelli, V., Grasso, V., Barbaccia, V., et al. Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. Acta Derm Venereol 92 (2012), 193–220.
81. Fujimi, A., Ibata, S., Kanisawa, Y., et al. Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia. J Dermatol 43 (2016), 106–107.
82. Boudadi, K., Chugh, R., Diffuse hypopigmentation followed by hyperpigmentation in an African American woman with hemangiopericytoma treated with dasatinib. J Clin Diagn Res 8:11 (2014), QD01–QD02.
83. Gathings, R., Lewallen, R., Yosipovitch, G., Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature. Acta Derm Venereol 95 (2015), 197–200.
84. Sideras, K., Menefee, M.E., Burton, J.K., Erlichman, C., Bible, K.C., Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 28 (2010), e312–e313.
85. Hartmann, J.T., Kanz, L., Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol 144 (2008), 1525–1526.
86. Al Enazi, M.M., Kadry, R., Mitwali, H., Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. J Am Acad Dermatol 61 (2009), 905–906.
87. Alonso-Castro, L., Rios-Buceta, L., Vano-Galvan, S., Moreno, C., Soria-Rivas, A., Jaen, P., Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma. J Am Acad Dermatol 69:1 (2013), e28–e29.
88. Wolner, Z.J., Marghoob, A.A., Pulitzer, M.P., Postow, M.A., Marchetti, M.A., A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol, 2017, 10.1111/bjd.15354 [Epub ahead of print].
89. Kagimoto, Y., Mizuashi, M., Kikuchi, K., Aiba, S., Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate. Int J Dermatol 53 (2014), e161–e162.
90. Resende, R.G., Teixeira, R.G.L., Vasconcelos, F.O., Silva, M.E.S., Abreu, M.H.G., Gomez, R.S., Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg 40 (2012), e140–e143.
91. Song, H.S., Kang, H.Y., Imatinib mesylate-induced hyperpigmentation of the nose and palate. Ann Dermatol 26 (2014), 532–533.
92. Dasanu, C.A., Dutcher, J., Alexandrescu, D.T., Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 100 (2007), 328–330.
93. Kong, H.H., Fine, H.A., Stern, J.B., Chanco Turner, M.L., Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 145 (2009), 923–925.
94. Brooks, S., Linehan, W.M., Srinivasan, R., Kong, H.H., Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol 147 (2011), 364–365.
95. Cheng, Y.P., Chen, H.J., Chiu, H.C., Erlotinib-induced hair repigmentation. Int J Dermatol 53 (2014), e55–e57.
96. Rodriguez, N.A., Ascaso, F.J., Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer. J Clin Oncol 29 (2011), e532–e533.
97. Mariani, S., Abruzzese, E., Basciani, S., et al. Reversible hair depigmentation in a patient treated with imatinib. Leuk Res 35:6 (2011), e64–e66.
98. Sun, A., Akin, R.S., Cobos, E., Smith, J., Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 8 (2009), 395–398.
99. Samimi, S., Chu, E., Seykora, J., et al. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 149 (2013), 637–639.
100. Kobayashi, E., Koyama, T., Kobayashi, K., Setsu, N., Kawashima, M., Kawai, A., Reversible hair depigmentation in a Japanese female treated with pazopanib. J Dermatol 41 (2014), 1021–1022.
101. Sibaud, V., Munsch, C., Lamant, L., Eruptive nevi and hair depigmentation related to regorafenib. Eur J Dermatol 25 (2015), 85–86.
102. Brzezniak, C., Szabo, E., Sunitinib-associated hair depigmentation. N Engl J Med, 370, 2014, e27.
103. Huan, T.C., Ho, C.L., Blue-black discoloration of the nails associated with gefitinib. Acta Clin Belg, 66, 2011, 72.
104. Steele, J.C., Triantafyllou, A., Rajlawat, B.P., Field, E.A., Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib. Clin Exp Dermatol 37 (2012), 432–447.
105. Prabhash, K., Biswas, G., Prasad, N., et al. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 72 (2006), 63–64.
106. Mcpherson, T., Sherman, V., Turner, R., Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 23 (2009), 82–83.
107. Peuvrel, L., Quereux, G., Brocard, A., Saint-Jean, M., Dreno, B., Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Dermatology 224 (2012), 204–208.
108. Roeker, L.E., Wolanskyj, A.P., Imatinib-associated melanosis of the palate. Am J Hematol, 89, 2014, 564.
109. Wong, M., Sade, S., Gilbert, M., Klieb, H.B., Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Dermatol Online J, 17(6), 2011, 4.
110. Li, C.C., Malik, S.M., Blaeser, B.F., et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 6 (2012), 290–295.
111. Lewis, D.M., Diffuse pigmentation of the palate. J Okla Dent Assoc 100:8 (2009), 24–25.
112. Khoo, T.L., Catalano, A., Supple, S., et al. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leuk Lymphoma 54 (2013), 186–188.
113. Mattsson, U., Halbritter, S., Serikoff, E.M., Christerson, L., Warfvinge, G., Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:5 (2011), e12–e16.
114. Yu, Y.H., Shere, Y., Vigneswaran, N., Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy. Tex Dent J 129 (2012), 764–765.